Abstract: The present invention relates to artificial Antigen Presenting Cells (aAPCs) comprising artificial Antigen Presenting Molecules (aAPMs) and, in particular, comprising dimers of the aAPMs as well as to methods for producing aAPCs. The invention further relates to compositions comprising the aAPCs and to vectors encoding the aAPMs of the aAPCs. Embodiments of the invention have been particularly developed for use in assays for determining an antigen-specific T cell response or a plurality of antigen-specific T cell responses and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.

Abstract: The present invention relates to a method for color visualization and separation of a natural and medical image comprising pixels defined by color pixel vector a=[a1a2, a3] in a Cartesian color space (e.g. RGB), where the color pixel vector is represented by a pure quaternion q=+a1i+a2j+a3k with i,j, k satisfying: i2=j2=k2=ijk=?1, ij=?ji=k,jk=?kj=i, ki=?ik=j and the image is decomposed into q+ and q using the orthogonal 2D planes split concept according to: (formula (I)) wherein/and g are pure unit quaternions or f and g describe interactively determined or computed colors (s1, s2). The method allows not only visualizing and separating certain colors in a digital image in a rapid fashion, but also permits a flexible definition pertinent to the kind of colors that can be visualized or separated by defining the corresponding decompositions by means of pure unit quaternions/and g. Colors s1, s2 can be defined manually or computed automatically from the image.

Abstract: The present invention relates to a method for color visualization and separation of a natural and medical image comprising pixels defined by color pixel vector a=[a1a2, a3] in a Cartesian color space (e.g. RGB), where the color pixel vector is represented by a pure quaternion q=+a1i+a2j+a3k with i,j, k satisfying: i2=i2=k2=ijk=?1, ij=?ji=k,jk=?kj=i, ki=?ik=j and the image is decomposed into q+ and q using the orthogonal 2D planes split concept according to: (formula (I)) wherein/and g are pure unit quaternions or f and g describe interactively determined or computed colors (s1, s2). The method allows not only visualizing and separating certain colors in a digital image in a rapid fashion, but also permits a flexible definition pertinent to the kind of colors that can be visualized or separated by defining the corresponding decompositions by means of pure unit quaternions/and g. Colors s1, s2 can be defined manually or computed automatically from the image.

Abstract: The present invention relates to a modified viral structural protein (VSP) as a tool for specifically targeting a chimeric antigen receptor (CAR) expressed on cells of the immune system. The modified VSPs can assemble into virus like particles (VLP). Exposed areas of the VSPs are modified to comprise in a region located atthe surface of a higher order structure, e.g. such as a capsomeric structure, a capsid, a VLP, a viral vector or a virus, a ligand specifically binding to a CAR (LCAR). The present invention thus, provides a modified VSP. The invention also relates to a nucleic acid encoding said VSP. Further, the invention relates to a capsomeric structure, a capsid, a VLP, a viral vector or a virus comprising at least one VSP. Further, the invention relates to a pharmaceutical composition comprising the VSP, the nucleic acid, the capsomeric structure, the capsid, the VLP, the viral vector or the virus comprising at least one VSP.

Abstract: The present invention relates to CCRS antagonists for use in the treatment of cancer, either in monotherapy or in combination therapy. The invention also relates to methods for determining whether a subject suffering from cancer benefits from an ongoing therapeutic treatment with a CCRS antagonist or whether a subject suffering from cancer will benefit from a planned therapeutic treatment with a CCRS antagonist.

Abstract: The present invention relates to CCRS antagonists for use in the treatment of cancer, either in monotherapy or in combination therapy. The invention also relates to methods for determining whether a subject suffering from cancer benefits from an ongoing therapeutic treatment with a CCRS antagonist or whether a subject suffering from cancer will benefit from a planned therapeutic treatment with a CCRS antagonist.

Abstract: The present invention relates to the field of treatment efficacy prediction in patients with malignant diseases. More precisely, this invention relates to the prediction of the efficacy of a treatment in cancer patients, based on the precise quantification of several biological markers that are related to the innate and adaptive immune response of said patient against said cancer.